Skip to main content
65°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Harrow Inc
(NQ:
HROW
)
45.02
-1.45 (-3.12%)
Official Closing Price
Updated: 4:15 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Harrow Inc
< Previous
1
2
3
4
Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 24, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 24, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 23, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
February 23, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm
February 22, 2023
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
February 22, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Harrow Launches Next-Generation Compounded Atropine Formulations
February 15, 2023
From
Harrow
Via
Business Wire
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023
February 02, 2023
From
Harrow
Via
Business Wire
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
January 23, 2023
From
Harrow
Via
Business Wire
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
January 05, 2023
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
December 21, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Secures Capital to Close Recently Announced Acquisition
December 16, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
December 14, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Prices $25 Million Offering
December 14, 2022
From
Harrow
Via
Business Wire
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
December 14, 2022
From
Harrow
Via
Business Wire
Harrow and iOR Partners Expand National Product Supply Agreement
November 30, 2022
From
Harrow
Via
Business Wire
Harrow Announces Third Quarter 2022 Financial Results
November 14, 2022
From
Harrow
Via
Business Wire
Harrow Launches Atropine.com
November 10, 2022
From
Harrow
Via
Business Wire
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 28, 2022
From
Harrow
Via
Business Wire
Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300
October 27, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Sells Non-Ophthalmic Compounding Business
October 05, 2022
From
Harrow
Via
Business Wire
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 29, 2022
From
Harrow
Via
Business Wire
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
September 27, 2022
From
Harrow
Via
Business Wire
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 11, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces Second Quarter 2022 Financial Results
August 09, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
July 27, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
June 24, 2022
From
Harrow Health, Inc.
Via
Business Wire
Harrow Health Announces First Quarter 2022 Financial Results
May 05, 2022
From
Harrow Health, Inc.
Via
Business Wire
Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation
May 04, 2022
From
Melt Pharmaceuticals, Inc.
Via
Business Wire
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
April 22, 2022
From
Harrow Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.